Osteoporosis Management

Diagnosis and Treatment

• A T-score of -3.5 at the lumbar spine, femoral neck, or total hip confirms the diagnosis of severe osteoporosis, representing a significant fracture risk that requires prompt intervention, according to World Health Organization criteria 1
• The World Health Organization recommends immediate pharmacologic treatment with a bisphosphonate as first-line therapy, along with calcium and vitamin D supplementation, for patients with a T-score of -3.5 1
• Patients with a T-score between -1.0 and -2.4 are considered to have moderate fracture risk, with significant BMD loss over time being a factor in determining this risk 2, 3, 4
• The American College of Physicians and other guideline societies consider factors such as age, T-score, and rate of bone loss when assessing fracture risk 5, 6

Nutrition and Lifestyle

• Calcium supplementation of 1000-1200 mg daily (total from diet and supplements) and vitamin D supplementation of 800-1000 IU daily (target serum level ≥20 ng/ml) are recommended to improve bone health 7, 5, 6
• Weight-bearing and resistance training exercises are recommended to improve bone health, along with nutritional counseling to address low BMI and promote overall health 7, 6, 8
• Smoking cessation and limiting alcohol intake to 1-2 drinks per day are recommended to reduce fracture risk 7, 6

Medication Efficacy

• Bisphosphonates have been shown to reduce vertebral fracture risk by up to 70% and non-vertebral fracture risk by 20-30% in patients with osteoporosis 9
• Low-quality evidence suggests that bisphosphonate treatment in women with osteopenia near the osteoporosis threshold may reduce fracture risk, with the benefit of fracture reduction likely similar across all agents in this class 5

Treatment Considerations

• Inadequate calcium/vitamin D supplementation can reduce the effectiveness of osteoporosis medications 7
• The American College of Physicians recommends treatment for osteopenic women 65 years or older at high risk for fracture, with oral bisphosphonate therapy (alendronate 70mg weekly or risedronate 35mg weekly) as first-line treatment 5, 6
• Alternative treatment options include IV bisphosphonates (zoledronic acid) as second-line treatment, denosumab 60mg subcutaneously every 6 months, and teriparatide for patients with very high fracture risk 6, 5
• Guideline societies, including the American College of Physicians and the National Osteoporosis Foundation, recommend pharmacologic treatment for all adults with T-scores ≤-2.5 10, 5
• The balance of benefits and harms of treating osteopenia is most favorable when fracture risk is high, with the risk for severe adverse effects increasing with prolonged use of bisphosphonates 5, 6
• Treatment decisions should consider the patient's age, T-score, and rate of bone loss, with special consideration for patients with unique barriers, such as those with Down syndrome 5, 6

Treatment Monitoring and Follow-up

• BMD testing every 1-2 years is recommended to assess treatment efficacy, along with clinical assessment every 6-12 months to monitor treatment adherence and side effects 3, 4, 6
• Vertebral fracture assessment (VFA) or spinal x-ray is recommended to detect asymptomatic vertebral fractures, and evaluation of calcium and vitamin D status is necessary to ensure adequate supplementation 3, 4, 6